Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 4
2009 4
2010 7
2011 22
2012 45
2013 83
2014 146
2015 181
2016 210
2017 221
2018 282
2019 263
2020 231
2021 277
2022 276
2023 181
2024 212
2025 209
2026 144

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,671 results

Results by year

Filters applied: . Clear all
Page 1
Afatinib.
Wecker H, Waller CF. Wecker H, et al. Recent Results Cancer Res. 2018;211:199-215. doi: 10.1007/978-3-319-91442-8_14. Recent Results Cancer Res. 2018. PMID: 30069769 Review.
Afatinib (BIBW 2992, US: Gilotrif(TM), other countries: Giotrif ) is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. ...Further investigations for the treatment of many other tumors with afatinib, e.g., HNSCC and breast …
Afatinib (BIBW 2992, US: Gilotrif(TM), other countries: Giotrif ) is an irreversible blocker of the ErbB family, acting at the tyrosi …
Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review.
Jiang Y, Fang X, Xiang Y, Fang T, Liu J, Lu K. Jiang Y, et al. Curr Oncol. 2023 May 28;30(6):5337-5349. doi: 10.3390/curroncol30060405. Curr Oncol. 2023. PMID: 37366888 Free PMC article. Review.
Currently, with the use of third-generation EGFR-TKIs, afatinib is no longer clinically indicated as the first choice for patients with NSCLC who have EGFR-sensitive mutations. However, afatinib showed a considerable inhibitory effect in NSCLC patients with uncommon …
Currently, with the use of third-generation EGFR-TKIs, afatinib is no longer clinically indicated as the first choice for patients wi …
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings.
Harvey RD, Adams VR, Beardslee T, Medina P. Harvey RD, et al. J Oncol Pharm Pract. 2020 Sep;26(6):1461-1474. doi: 10.1177/1078155220931926. Epub 2020 Jun 20. J Oncol Pharm Pract. 2020. PMID: 32567494 Free PMC article. Review.
The second-generation, irreversible ErbB-family blocker, afatinib, has been extensively studied in the context of EGFRm+ NSCLC. Results from the LUX-Lung 3 and 6 studies showed that afatinib was more active and better tolerated than chemotherapy in patients with tum …
The second-generation, irreversible ErbB-family blocker, afatinib, has been extensively studied in the context of EGFRm+ NSCLC. Resul …
Afatinib and lung cancer.
Jain P, Khanal R, Sharma A, Yan F, Sharma N. Jain P, et al. Expert Rev Anticancer Ther. 2014 Dec;14(12):1391-406. doi: 10.1586/14737140.2014.983083. Expert Rev Anticancer Ther. 2014. PMID: 25417728 Review.
Based on these results, afatinib was recently approved for the first-line treatment of NSCLC patients with EGFR mutation. This article summarizes current status of preclinical and clinical development of afatinib in NSCLC....
Based on these results, afatinib was recently approved for the first-line treatment of NSCLC patients with EGFR mutation. This articl …
Afatinib-induced toxic epidermal necrolysis: A case report with a literature review.
Belančić A, Hlača N, Peternel S, Golčić M, Prpić-Massari L, Vlahović-Palčevski V. Belančić A, et al. Br J Clin Pharmacol. 2024 Aug;90(8):2030-2033. doi: 10.1111/bcp.16114. Epub 2024 May 27. Br J Clin Pharmacol. 2024. PMID: 38803188 Free article. Review.
We present a 70-year-old female patient diagnosed with epidermal growth factor receptor-mutated metastatic non-small cell lung cancer (T4N2M1a), who developed afatinib-induced toxic epidermal necrolysis (TEN). We have also performed a PubMed/Medline literature review to de …
We present a 70-year-old female patient diagnosed with epidermal growth factor receptor-mutated metastatic non-small cell lung cancer (T4N2M …
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
Lu S, Shih JY, Jang TW, Liam CK, Yu Y. Lu S, et al. Adv Ther. 2021 May;38(5):2038-2053. doi: 10.1007/s12325-021-01696-9. Epub 2021 Mar 17. Adv Ther. 2021. PMID: 33730350 Free PMC article. Review.
Evidence from real-world studies with afatinib in this patient population supports findings from randomized controlled trials (RCTs) showing that afatinib is associated with more favorable outcomes compared with the first-generation EGFR TKIs. ...In this article, we …
Evidence from real-world studies with afatinib in this patient population supports findings from randomized controlled trials (RCTs) …
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, Grossi F. Tagliamento M, et al. Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062. doi: 10.1080/14656566.2018.1540591. Epub 2018 Nov 3. Expert Opin Pharmacother. 2018. PMID: 30392436 Review.
AREAS COVERED: This review summarizes the potential roles of erlotinib and afatinib in SCC of the lung. The authors explore the rationale of targeting EGFR in SCC and the pharmacological properties of erlotinib and afatinib. ...Particular focus is given to the LUX-L …
AREAS COVERED: This review summarizes the potential roles of erlotinib and afatinib in SCC of the lung. The authors explore the ratio …
Afatinib in the treatment of breast cancer.
Hurvitz SA, Shatsky R, Harbeck N. Hurvitz SA, et al. Expert Opin Investig Drugs. 2014 Jul;23(7):1039-47. doi: 10.1517/13543784.2014.924505. Epub 2014 May 29. Expert Opin Investig Drugs. 2014. PMID: 24870559 Review.
This article also describes the data available for afatinib in breast cancer from preclinical analyses, published Phase I and II trials to ongoing and upcoming Phase II and III studies. ...The successful development of afatinib in breast cancer will thus depend on a …
This article also describes the data available for afatinib in breast cancer from preclinical analyses, published Phase I and II tria …
Afatinib in squamous cell carcinoma of the head and neck.
Specenier P, Vermorken J. Specenier P, et al. Expert Opin Pharmacother. 2016 Jun;17(9):1295-301. doi: 10.1080/14656566.2016.1183647. Epub 2016 May 19. Expert Opin Pharmacother. 2016. PMID: 27160335 Review.
INTRODUCTION: Recently new data on the efficacy of afatinib in head and neck squamous cell carcinoma (HNSCC) have been published. AREAS COVERED: We searched the literature for published and ongoing studies with afatinib in HNSCC. Phase I data and results of phase II …
INTRODUCTION: Recently new data on the efficacy of afatinib in head and neck squamous cell carcinoma (HNSCC) have been published. ARE …
Afatinib: An overview of its clinical development in non-small-cell lung cancer and other tumors.
Giordano P, Manzo A, Montanino A, Costanzo R, Sandomenico C, Piccirillo MC, Daniele G, Normanno N, Carillio G, Rocco G, Bianco R, Perrone F, Morabito A. Giordano P, et al. Crit Rev Oncol Hematol. 2016 Jan;97:143-51. doi: 10.1016/j.critrevonc.2015.08.016. Epub 2015 Aug 12. Crit Rev Oncol Hematol. 2016. PMID: 26318094 Review.
Afatinib is an oral, irreversible, tyrosine kinase inhibitor (TKI) of EGFR, HER2 and HER4. ...Afatinib failed to demonstrate an improvement in overall survival in unselected heavily pretreated NSCLC patients (Lux-Lung-1). ...
Afatinib is an oral, irreversible, tyrosine kinase inhibitor (TKI) of EGFR, HER2 and HER4. ...Afatinib failed to demonstrate a …
2,671 results